Selected article for: "acute respiratory syndrome and swine influenza"
Author: Zumla, Alimuddin; Memish, Ziad A; Maeurer, Markus; Bates, Matthew; Mwaba, Peter; Al-Tawfiq, Jaffar A; Denning, David W; Hayden, Frederick G; Hui, David S
Title: Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options
  • Cord-id: oigyut2k
  • Document date: 2014_9_1
    • ID: oigyut2k
    Snippet: The emergence and spread of antimicrobial-resistant bacterial, viral, and fungal pathogens for which diminishing treatment options are available is of major global concern. New viral respiratory tract infections with epidemic potential, such as severe acute respiratory syndrome, swine-origin influenza A H1N1, and Middle East respiratory syndrome coronavirus infection, require development of new antiviral agents. The substantial rise in the global numbers of patients with respiratory tract infect
    Document: The emergence and spread of antimicrobial-resistant bacterial, viral, and fungal pathogens for which diminishing treatment options are available is of major global concern. New viral respiratory tract infections with epidemic potential, such as severe acute respiratory syndrome, swine-origin influenza A H1N1, and Middle East respiratory syndrome coronavirus infection, require development of new antiviral agents. The substantial rise in the global numbers of patients with respiratory tract infections caused by pan-antibiotic-resistant Gram-positive and Gram-negative bacteria, multidrug-resistant Mycobacterium tuberculosis, and multiazole-resistant fungi has focused attention on investments into development of new drugs and treatment regimens. Successful treatment outcomes for patients with respiratory tract infections across all health-care settings will necessitate rapid, precise diagnosis and more effective and pathogen-specific therapies. This Series paper describes the development and use of new antimicrobial agents and immune-based and host-directed therapies for a range of conventional and emerging viral, bacterial, and fungal causes of respiratory tract infections.

    Search related documents:
    Co phrase search for related documents
    • acinetobacter baumannii and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • acinetobacter baumannii and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7
    • acinetobacter baumannii and adenovirus rhinovirus: 1
    • acinetobacter baumannii and adjunctive therapy: 1
    • acinetobacter spp and acute respiratory distress syndrome: 1
    • acinetobacter spp and adjunctive therapy: 1
    • activity show and acute respiratory distress syndrome: 1, 2, 3
    • activity show and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and add therapy: 1, 2, 3, 4
    • acute respiratory distress syndrome and adenovirus rhinovirus: 1
    • acute respiratory distress syndrome and adjunct therapy: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory distress syndrome and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute sars cov respiratory syndrome coronavirus and adaptive transfer: 1
    • acute sars cov respiratory syndrome coronavirus and add therapy: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and adenovirus rhinovirus: 1, 2, 3, 4, 5, 6, 7
    • acute sars cov respiratory syndrome coronavirus and adenovirus rhinovirus respiratory syncytial virus: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and adjunct therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10